From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
2-{[(2E)-3-(3,4-dimethoxyphenyl)prop-2- enoyl]amino}benzoic acid
Clinical data
AHFS/ International Drug Names
Legal status
  • Prescription only
Routes Oral
CAS number 53902-12-8
ATC code None
PubChem CID 5282230
Chemical data
Formula C18H17NO5 
Mol. mass 327.33 g/mol

Tranilast (INN, brand name Rizaben) is an antiallergic drug. It was developed by Kissei Pharmaceuticals and was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993.[1] It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

In-vitro it reduces collagen synthesis in fibroblasts,[2] and inhibits growth of neurofibroma cells.[3]

In-vitro it inhibits the production of interleukin-6 in endothelial cells.[4]

It is relatively safe and well tolerated by most patients at doses of up to 600 mg/day for months.

After promising results in three small trial Tranilast was studied in a major clinical trial (the PRESTO trial) for prevention of restenosis after percutaneous transluminal coronary revascularization, but was not found effective for that application.[5]

It has also been investigated for use as an antiproliferative drug on drug-eluting stents.

A phase II trial is recruiting rheumatoid arthritis patients.[6]

A phase III trial is evaluating tranilast for Pterygium.[7]


  1. ^
  2. ^
  3. ^ "Tranilast, an Anti-Allergic Drug, Down-Regulates the Growth of Cultured Neurofibroma Cells Derived from Neurofibromatosis Type 1" 2009
  4. ^ "Tranilast Inhibits Cytokine-Induced Nuclear Factor κB Activation in Vascular Endothelial Cells" 2002
  5. ^ "Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial" 2002
  6. ^
  7. ^

External links[edit]